Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/1999
03/18/1999CA2302148A1 Human papilloma virus inhibition by anti-sense oligonucleotides
03/18/1999CA2301979A1 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor
03/18/1999CA2301173A1 Cysteine rich receptors-train
03/18/1999CA2296358A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
03/18/1999CA2247551A1 Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them
03/17/1999EP0902025A2 Benzothiophenes for treatment of estrogen related conditions
03/17/1999EP0902022A1 Novel benzofuranone derivatives and process for producing the same
03/17/1999EP0901492A1 Taxane derivatives, the preparation thereof and formulations containing them
03/17/1999EP0901489A1 Antagonists of gonadotropin releasing hormone
03/17/1999EP0901483A2 Benzofurans and benzopyrans as chronobiological agents
03/17/1999EP0901482A1 Benzofuran carboxamides and their therapeutic use
03/17/1999EP0901462A1 Bi-aromatic compounds, compositions containing them and uses
03/17/1999EP0901379A2 Type-2 chemokine binding proteins and methods of use therefor
03/17/1999EP0901378A1 Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid
03/17/1999EP0901373A1 Alpha v Beta 3 ANTAGONISTS
03/17/1999EP0901370A1 Stimulation of immune response with low doses of il-2
03/17/1999EP0737070A4 Vitamin d 3? analogues and pathway to mediate disorders
03/17/1999EP0678087B1 Compounds having selective activity for retinoid x receptors, and means for modulation of processes mediated by retinoid x receptors
03/17/1999EP0616536B1 Use of decorin or biglycan for the manufacture of a medicament in the treatment of diabetes-associated pathology
03/17/1999CN1211254A Fused pyrrolo (2,3-C) carbazole-6-ones which potentiate activity of gamma interferon
03/17/1999CN1211240A Quinazoline derivatives as antitumor agents
03/17/1999CN1211185A Sulfate conjugates of ursodeoxychloric acid, and their beneficial use in inflammatory disorders and other applications
03/17/1999CN1211180A Method of treatment with compounds having RAG 'alpha' receptor specific or selective activity
03/17/1999CN1210741A Method for preparing radiopharmaceutical kit for bone tumour curing or diagnosis
03/17/1999CA2247764A1 Bifunctional water-soluble polymer derivative and complex containing it
03/16/1999US5883293 Conformationally constrained backbone cyclized peptide analogs
03/16/1999US5883270 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
03/16/1999US5883230 Multidomain hematopoiesis stimulators
03/16/1999US5883133 Cardiovascular disorders
03/16/1999US5883124 Administering phenylacetic acid derivative and retinoid to treat tumors
03/16/1999US5883118 Anticarcinogenic agents
03/16/1999US5883116 3-(2'-alkoxybenzylidenyl)-2-indolinone and analogues thereof for the treatment of disease
03/16/1999US5883114 Indolocarbazole imides and the use thereof
03/16/1999US5883113 Tyrosine kinase inhibitors; antiproliferative and anticarcinogenic agents; diabetes, arthritis, restenosis, atherosclerosis
03/16/1999US5883075 Hypotensive agent cyclic peptides
03/16/1999US5882897 yitJ
03/16/1999US5882887 Proteins for genetic engineering
03/16/1999US5882876 Amino acid sequences in proteins and markers of cancer cells
03/16/1999US5882860 Hybridization of nucleic acid derived from cell with polynucleotide; genetic engineering; suppressing gene expression
03/16/1999US5882654 Polyvalent melanoma vaccine
03/16/1999US5882648 Methods of disease inhibition using acid polysaccharides extracted from nutshells
03/16/1999CA2244232A1 Novel def
03/16/1999CA2109861C 6,7-modified paclitaxels
03/16/1999CA1340447C Pipecolic acid-containing peptolides, their preparation and pharmaceutical compositions containing them
03/11/1999WO1999012039A1 Prognostic protocol
03/11/1999WO1999011798A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
03/11/1999WO1999011790A1 Tumor necrosis factor receptor ztnfr-6
03/11/1999WO1999011788A1 Kringle1
03/11/1999WO1999011782A1 T-cell membrane protein (tirc7), peptides and antibodies derived therefrom and uses thereof
03/11/1999WO1999011667A1 METHYLATED, SmD HOMOLOGOUS PEPTIDES, REACTIVE WITH THE ANTIBODIES FROM SERA OF LIVING BEINGS AFFECTED WITH SYSTEMIC LUPUS ERYTHEMATOSUS
03/11/1999WO1999011663A1 HUMAN DEFENSIN DEF-X, GENE AND DNAc, COMPOSITION CONTAINING SAME AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
03/11/1999WO1999011649A2 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
03/11/1999WO1999011646A1 Optically pure camptothecin analogues, optically pure synthesis intermediate and method for preparing same
03/11/1999WO1999011645A1 Poly(adp-ribose) polymerase ('parp') inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
03/11/1999WO1999011628A1 Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity
03/11/1999WO1999011626A1 Integrin receptor antagonists
03/11/1999WO1999011624A1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
03/11/1999WO1999011620A1 Branched alkoxy-subsituted 2-aminopyridines as nos inhibitors
03/11/1999WO1999011608A1 Malonic acid based matrix metalloproteinase inhibitors
03/11/1999WO1999011293A1 50 human secreted proteins
03/11/1999WO1999011278A1 Robinia pseudoacacia lectin and its uses
03/11/1999WO1999011240A1 Carotenoid microemulsions
03/11/1999WO1998044788A3 Animal model for evaluation of vaccines
03/11/1999WO1998042847A3 Papilloma virus main capsid protein and the use thereof in diagnosis, therapy and vaccination
03/11/1999WO1998033509A3 Useful properties of human lactoferrin and variants thereof
03/11/1999CA2304117A1 Integrin receptor antagonists
03/11/1999CA2302405A1 Prognostic protocol
03/11/1999CA2302037A1 Malonic acid based matrix metalloproteinase inhibitors
03/11/1999CA2301848A1 Robinia pseudoacacia lectin and its uses
03/11/1999CA2296758A1 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
03/11/1999CA2294133A1 Poly(adp-ribose) polymerase ("parp") inhibitors, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
03/11/1999CA2294118A1 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
03/11/1999CA2294110A1 Alkoxy-substituted compounds, methods, and compositions for inhi biting parp activity
03/11/1999CA2294074A1 Parp inhibitors, pharmaceutical compositions comprising same, and methods of using same
03/10/1999EP0900849A1 Receptor-mediated gene transfer system for targeting tumor gene therapy
03/10/1999EP0900211A1 Thiadiazolyl(thio)ureas useful as matrix metalloprotease inhibitors
03/10/1999EP0900201A1 Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
03/10/1999EP0900198A1 New vitamin d derivatives with carbo- or heterocyclic substituents at c-25, a process for their production, intermediate products and their use for producing medicaments
03/10/1999EP0900081A1 Inhibitors of farnesyl-protein transferase
03/10/1999EP0773951B1 Dinucleoside-5',5'-pyrophosphates
03/10/1999EP0722438B1 Hydroxamic acid derivatives as inhibitors of cytokine production
03/10/1999EP0708785B1 Heparin derivatives having antimetastatic activity
03/10/1999EP0505400B1 N-substituted naphthalamides, their production and use
03/10/1999EP0505357B1 Method for antibody targeting of diagnostic or therapeutic agents
03/10/1999CN1210535A Taxane derivatives having pyridil substituted C13 side chain, their preparation and their use as anti-tumor agents
03/10/1999CN1210525A Taxoids, preparation thereof and pharmaceutical compositions containing same
03/10/1999CN1210517A Hydroxamic acid derivatives for use with treatment of diseases related to connective tissue degradation
03/10/1999CN1210110A Active peptide for promoting immunization function and usage thereof
03/10/1999CN1042429C 5-(1-fluoro-vinyl-1H-pyrimidine-2,4-dione derivatives, medicinal composition and preparation thereof
03/09/1999US5880284 Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
03/09/1999US5880263 Human chemotactic protein
03/09/1999US5880160 Antiproliferative, antineoplastic, antiinflammatory and muscle relaxant activities
03/09/1999US5880152 Inflammatory bowel disease
03/09/1999US5880145 Photodynamic therapy
03/09/1999US5880141 Controlling, modulating and inhibiting tyrosine kinase signal transduction
03/09/1999US5880130 Treatment of cell-proliferation diseases
03/09/1999US5880115 Steroid sulfatase inhibitors and methods for making and using the same
03/09/1999US5880113 Antiproliferative agents, cell differentiation inducers
03/09/1999US5880097 Tethered prodrugs
03/09/1999US5879911 Cell surface protein expressed on human cortical thymocyte and their use
1 ... 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 ... 2211